Get the Stockscreener App
460.83
1.88%
-8.82
After Hours:
460.83
Vertex Pharmaceuticals Inc stock is traded at $460.83, with a volume of 2.11M.
It is down -1.88% in the last 24 hours and up +4.43% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$469.65
Open:
$467.44
24h Volume:
2.11M
Relative Volume:
1.40
Market Cap:
$118.34B
Revenue:
$11.10B
Net Income/Loss:
$-988.90M
P/E Ratio:
-117.56
EPS:
-3.92
Net Cash Flow:
$-1.26B
1W Performance:
+0.51%
1M Performance:
+4.43%
6M Performance:
+4.57%
1Y Performance:
-6.95%
1-Day Range:
$460.73
$471.00
1-Week Range:
$458.88
$480.00
52-Week Range:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals' (VRTX) Upcoming Earnings and Strategic Momentum: A Deep Dive into Long-Term Growth Potential Amid Pipeline Advancements and Financial Resilience - AInvest
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
How does Vertex Pharmaceuticals Incorporated generate profit in a changing economyMaximize your gains with expert trading tips - jammulinksnews.com
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment - MSN
The 3 Things That Matter for Vertex Pharmaceuticals Now - AOL.com
The 3 Things That Matter for Vertex Pharmaceuticals Now - The Motley Fool
Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q1 Earnings? - FinancialContent
Should I hold or sell Vertex Pharmaceuticals Incorporated stock in 2025Rapid growth opportunities - jammulinksnews.com
Why is Vertex Pharmaceuticals Incorporated stock attracting strong analyst attentionInvest confidently with real-time data - jammulinksnews.com
Published on: 2025-07-27 22:21:17 - jammulinksnews.com
Is Vertex Pharmaceuticals Incorporated a growth stock or a value stockSuperior portfolio returns - jammulinksnews.com
Truist Financial Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know - MSN
Vertex Bets Big On Rare Diseases And Pain Medicine - Finimize
What drives Vertex Pharmaceuticals Incorporated stock priceHigh-octane financial growth - Autocar Professional
Can Vertex Pharmaceuticals Incorporated stock recover from recent declineFree Risk Assessment Services - jammulinksnews.com
Three Indian American-led firms among TIME100 Most Influential Companies - The American Bazaar
Vertex Pharmaceuticals Incorporated Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Advances Cystic Fibrosis Treatment With ALYFTREK Approval in Canada - Yahoo Finance
What analysts say about Vertex Pharmaceuticals Incorporated stockFree Stock Market Return Analysis - jammulinksnews.com
Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Cystic Fibrosis Pipeline Outlook 2025: Insights into Drug Development and Leading 50+ Companies - The Globe and Mail
Vertex Pharmaceuticals: Pioneering Orphan Drug Innovation in Cystic Fibrosis and Cementing Market Leadership - AInvest
Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis - The Malaysian Reserve
Is Vertex Pharmaceuticals Incorporated a good long term investmentTriple-digit wealth increases - jammulinksnews.com
Vertex Pharmaceuticals (VRTX) Gets a Hold from Wells Fargo - The Globe and Mail
Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need To Know - Barchart.com
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - Yahoo Finance
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga
Vertex Pharmaceuticals (VRTX): Can Strong Catalysts Propel Outperformance Ahead of Earnings? - AInvest
Lobbying Update: $1,140,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq
Diabetic Neuropathic Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca, Eli Lilly and Company - Barchart.com
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharmaceuticals: Strong Growth Driven by Cystic Fibrosis Success and Strategic Expansions - TipRanks
Vertex Pharmaceuticals Surges to 213th in Trading Volume with $460 Million in Shares Traded Despite Stock Price Decline - AInvest
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
0.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):